相关实验视频

Updated: Jan 17, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

在治疗多发性硬化症时,从维生素B12和脂体信号通路中获得神经保护性交叉

Yasuyuki Kihara¹, Jerold Chun¹

¹Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA.

International immunology

|September 25, 2025

概括

像fingolimod这样的sphingosine 1-phosphate (S1P) 调节剂通过与中枢神经系统 (CNS) 中的维生素B12通路相互作用,影响多发性硬化症 (MS). 这表明MS和其他神经系统疾病中神经保护的新治疗点.

科学领域:

神经免疫学神经免疫学
细胞和分子神经科学
生物化学生物化学

背景情况:

多发性硬化症 (MS) 是一种中枢神经系统疾病,涉及神经炎症和神经退行.
像fingolimod一样的sphingosine 1-phosphate (S1P) 受体 (S1PR) 调节剂是MS的疾病修饰疗法 (DMT).
它们的机制涉及直接的中枢神经系统 (CNS) 对星球细胞的作用,超出了淋巴细胞封存.

研究的目的:

要突出新出现的证据,将S1P信号与维生素B12通路联系起来.
探索星球细胞中S1P1信号传递和CD320表达之间的功能相互作用.
确定MS和相关神经系统疾病的新型治疗策略.

主要方法:

基因表达变化的分析在即时早期的天体细胞 (ieAstrocytes).
研究S1P1信号与CD320之间的功能相互作用.
确定fingolimod/sphingosine,TCN2和CD320之间的物理相互作用.

主要成果:

在iAstrocytes中发现了S1P1信号与CD320表达之间的功能联系.
在fingolimod/sphingosine和转巴胺2 (TCN2) 之间确定了物理相互作用.
这种fingolimod/sphingosine-TCN2复合体可以强化CD320内部化.

结论:

中枢神经系统维生素B12水平在MS和潜在的其他神经系统疾病中至关重要.
这些发现解释了维生素B12缺乏和MS之间共享的神经症状.
针对脂和维生素B12途径之间的交叉可能会增强MS中神经保护.

关键词:

FTY72020的时间.在GPCR中,GPCR是指GPCR.在S1P中,它是S1P.在S1P1中,S1P1是什么?这就是fingolimod的意思.斯芬戈辛尼 (Sphingosine) 是一种神.

更多相关视频

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

相关概念视频

The Blood-brain Barrier

The Blood-brain Barrier

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...